London-based Hikma Pharmaceuticals has won approval to launch the first generic version of Vascepa (icosapent ethyl), after having key Amarin patents for the heart drug invalidated.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
13 August 2020 Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.
1 April 2020 A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.